Australia approves puberty blockers for trans youth in new interim guidance
Federal Health Minister Mark Butler asked the National Health and Medical Research Council (NHMRC) to review puberty blockers in 2025
By Aaron Sugg
Australia’s national health authority has released interim guidance backing puberty blockers for transgender young people under 18.
Titled ‘Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18’, the National Health and Medical Research Council (NHMRC) recommended that puberty blockers should remain an option for some trans young people.
The council stressed that decisions should be made through shared discussions involving the young person, their parents or carers, and healthcare professionals.
Puberty blockers should be issued after ‘shared decision-making’
“Shared decision-making involves young people, their parents or carers and clinicians discussing the available evidence, potential benefits and harms, and the young person’s individual circumstances and preferences before deciding together whether treatment is appropriate,” the council said.
NHMRC acting chief executive Prue Torrance said the guidance would help young people and their families make informed decisions about their care.
“Young people and their families should be able to have informed discussions with their healthcare professionals, supported by the best available evidence and clear, trustworthy clinical guidance,” she said.
“Puberty suppressants are one possible part of care, and decisions about their use need to be made through shared decision making that involves the individual young person, their parents or carers and clinicians.”
Federal Health Minister Mark Butler asks to review puberty blocker guidance
Federal Health Minister Mark Butler asked the National Health and Medical Research Council (NHMRC) to review puberty blockers last year.
Following the recent guidance, he said decisions about treatment must be supported by comprehensive health assessments and appropriate medical advice.
“Decisions about treatment with puberty suppressants should be informed by the provision of appropriate information to the young person and their parents or carers, a comprehensive health assessment, multidisciplinary input tailored by a healthcare team to the needs of the young person, and regular monitoring,” he said.
Butler condemns harmful noise
Butler acknowledged public concern but condemned unnecessary criticism, warning of the harm it could cause to vulnerable young people and their families.
“Not all of that public commentary and debate is always constructive, and frankly sometimes it runs the risk of being quite damaging, particularly damaging to the mental health of those young Australians and their families,” he said.
The interim advice is now open for public consultation, with submissions closing on January 18, 2027.
